Location [1]
Protein [2]
V-set domain-containing T-cell activation inhibitor 1
Synonyms [1]
PRO1291, B7-H4, B7X, VCTN1, B7h.5, B7S1, B7H4

VTCN1 is altered in 0.29% of all cancers with breast invasive ductal carcinoma and cutaneous melanoma having the greatest prevalence of alterations [3].

VTCN1 GENIE Cases - Top Diseases

The most common alterations in VTCN1 are VTCN1 Amplification (0.15%) and VTCN1 Loss (0.03%) [3].

VTCN1 GENIE Cases - Top Alterations

Significance of VTCN1 in Diseases

Breast Carcinoma +

Malignant Solid Tumor +

Endometrial Carcinoma +

Fallopian Tube Carcinoma +

Malignant Ovarian Epithelial Tumor +

Primary Peritoneal Carcinoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.